WEKO3
アイテム
{"_buckets": {"deposit": "cc59afac-4c35-4e3b-8225-b34a13aec300"}, "_deposit": {"created_by": 11, "id": "3559", "owners": [11], "pid": {"revision_id": 0, "type": "depid", "value": "3559"}, "status": "published"}, "_oai": {"id": "oai:shiga-med.repo.nii.ac.jp:00003559", "sets": ["79"]}, "author_link": ["7917", "675", "7562", "7918", "674", "677"], "item_4_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-05", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "4", "bibliographicPageEnd": "756", "bibliographicPageStart": "752", "bibliographicVolumeNumber": "43", "bibliographic_titles": [{}, {"bibliographic_title": "Biological \u0026 pharmaceutical bulletin", "bibliographic_titleLang": "en"}]}]}, "item_4_creator_3": {"attribute_name": "著者別名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "土手, 賢史"}], "nameIdentifiers": [{"nameIdentifier": "7562", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "平, 大樹"}], "nameIdentifiers": [{"nameIdentifier": "677", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50636959", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=50636959"}, {"nameIdentifier": "0000-0001-8344-2469", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0001-8344-2469"}]}, {"creatorNames": [{"creatorName": "野田, 哲史"}], "nameIdentifiers": [{"nameIdentifier": "674", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60865707", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=60865707"}]}, {"creatorNames": [{"creatorName": "寺田, 智祐"}], "nameIdentifiers": [{"nameIdentifier": "675", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10324641", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=10324641"}]}]}, "item_4_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Hypothyroidism is a well-established toxicity of small-molecule anti-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors. However, its association with anti-VEGF biologics is uncertain. The aim of this study was to investigate the incidence, time course, clinical features, and severity of thyroid dysfunction in patients receiving ramucirumab (an antiangiogenic VEGF receptor 2-binding monoclonal antibody). After retrospectively reviewing electronic medical records from September 2015 to December 2018 at Kyoto-Katsura Hospital, we identified 38 patients who received ramucirumab and had thyroid function testing available to review (case series). We also evaluated the change of thyroid-stimulating hormone (TSH) level during ramucirumab chemotherapy in 16 out of 38 patients who were regularly confirmed TSH (descriptive study). A total of 14 (36.8%) patients developed thyroid dysfunction (TSH \u003e10 mU/L) after ramucirumab chemotherapy. Thyroid autoantibodies were detected in one of the 10 patients (10.0%) who were tested for thyroid autoantibodies. The median time to onset of thyroid dysfunction after ramucirumab initiation was 275 (range, 63-553) days. Levothyroxine replacement was needed in 10 (71.4%) patients. Sixteen patients had thyroid function regularly monitored; the mean TSH level was significantly increased after ramucirumab chemotherapy compared with that at baseline (10.7 ± 10.0 mU/L vs. 4.1 ± 2.8 mU/L; p \u003c 0.01). Our findings indicate that ramucirumab can result in thyroid dysfunction. We propose that thyroid function testing should be performed regularly to detect hypothyroidism and guide its management in patients receiving ramucirumab chemotherapy.", "subitem_description_type": "Abstract"}]}, "item_4_description_42": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "Journal Article", "subitem_description_type": "Other"}]}, "item_4_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Pharmaceutical Society of Japan"}]}, "item_4_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "32238718", "subitem_relation_type_select": "PMID"}}]}, "item_4_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1248/bpb.b19-01071"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1248/bpb.b19-01071", "subitem_relation_type_select": "DOI"}}]}, "item_4_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2020 The Pharmaceutical Society of Japan"}]}, "item_4_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1347-5215", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "DOTE, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "7562", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YAMAGUCHI, Daisuke"}], "nameIdentifiers": [{"nameIdentifier": "7917", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "HIRA, Daiki"}], "nameIdentifiers": [{"nameIdentifier": "677", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50636959", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=50636959"}, {"nameIdentifier": "0000-0001-8344-2469", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0001-8344-2469"}]}, {"creatorNames": [{"creatorName": "NODA, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "674", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60865707", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=60865707"}]}, {"creatorNames": [{"creatorName": "KOBAYASHI, Yuka"}], "nameIdentifiers": [{"nameIdentifier": "7918", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "TERADA, Tomohiro"}], "nameIdentifiers": [{"nameIdentifier": "675", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10324641", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=10324641"}]}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "anti-vascular endothelial growth factor monoclonal antibody", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ramucirumab", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "thyroid dysfunction", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "vascular endothelial growth factor", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Thyroid Dysfunction Related to the Antiangiogenic VEGFR2-Binding Monoclonal Antibody Ramucirumab: A Series of 14 Cases and a Descriptive Study.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Thyroid Dysfunction Related to the Antiangiogenic VEGFR2-Binding Monoclonal Antibody Ramucirumab: A Series of 14 Cases and a Descriptive Study."}]}, "item_type_id": "4", "owner": "11", "path": ["79"], "permalink_uri": "http://hdl.handle.net/10422/00012680", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-05-29"}, "publish_date": "2020-05-29", "publish_status": "0", "recid": "3559", "relation": {}, "relation_version_is_last": true, "title": ["Thyroid Dysfunction Related to the Antiangiogenic VEGFR2-Binding Monoclonal Antibody Ramucirumab: A Series of 14 Cases and a Descriptive Study."], "weko_shared_id": -1}
Thyroid Dysfunction Related to the Antiangiogenic VEGFR2-Binding Monoclonal Antibody Ramucirumab: A Series of 14 Cases and a Descriptive Study.
http://hdl.handle.net/10422/00012680
http://hdl.handle.net/10422/000126800ed83a1b-675c-4d3d-a4e3-05160e660de1
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-05-29 | |||||
タイトル | ||||||
タイトル | Thyroid Dysfunction Related to the Antiangiogenic VEGFR2-Binding Monoclonal Antibody Ramucirumab: A Series of 14 Cases and a Descriptive Study. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | anti-vascular endothelial growth factor monoclonal antibody | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | ramucirumab | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | thyroid dysfunction | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | vascular endothelial growth factor | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
DOTE, Satoshi
× DOTE, Satoshi× YAMAGUCHI, Daisuke× HIRA, Daiki× NODA, Satoshi× KOBAYASHI, Yuka× TERADA, Tomohiro |
|||||
著者別名 |
土手, 賢史
× 土手, 賢史× 平, 大樹× 野田, 哲史× 寺田, 智祐 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Hypothyroidism is a well-established toxicity of small-molecule anti-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors. However, its association with anti-VEGF biologics is uncertain. The aim of this study was to investigate the incidence, time course, clinical features, and severity of thyroid dysfunction in patients receiving ramucirumab (an antiangiogenic VEGF receptor 2-binding monoclonal antibody). After retrospectively reviewing electronic medical records from September 2015 to December 2018 at Kyoto-Katsura Hospital, we identified 38 patients who received ramucirumab and had thyroid function testing available to review (case series). We also evaluated the change of thyroid-stimulating hormone (TSH) level during ramucirumab chemotherapy in 16 out of 38 patients who were regularly confirmed TSH (descriptive study). A total of 14 (36.8%) patients developed thyroid dysfunction (TSH >10 mU/L) after ramucirumab chemotherapy. Thyroid autoantibodies were detected in one of the 10 patients (10.0%) who were tested for thyroid autoantibodies. The median time to onset of thyroid dysfunction after ramucirumab initiation was 275 (range, 63-553) days. Levothyroxine replacement was needed in 10 (71.4%) patients. Sixteen patients had thyroid function regularly monitored; the mean TSH level was significantly increased after ramucirumab chemotherapy compared with that at baseline (10.7 ± 10.0 mU/L vs. 4.1 ± 2.8 mU/L; p < 0.01). Our findings indicate that ramucirumab can result in thyroid dysfunction. We propose that thyroid function testing should be performed regularly to detect hypothyroidism and guide its management in patients receiving ramucirumab chemotherapy. | |||||
書誌情報 |
en : Biological & pharmaceutical bulletin 巻 43, 号 4, p. 752-756, 発行日 2020-05 |
|||||
出版者 | ||||||
出版者 | Pharmaceutical Society of Japan | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1347-5215 | |||||
PMID | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 32238718 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1248/bpb.b19-01071 | |||||
関連名称 | 10.1248/bpb.b19-01071 | |||||
権利 | ||||||
権利情報 | © 2020 The Pharmaceutical Society of Japan | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal Article |